26 reports

China’s demand for Depression Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer...

  • Antidepressant
  • Depression
  • China
  • Industrial Production
  • Labour Force

Major Depressive Disorder - Epidemiology Forecast to 2029 Summary Major depressive disorder (MDD), also known as clinical depression or major depression, is widely recognized as a mood disorder that may lead to a variety of emotional and physical problems (Mayo Clinic, 2018).MDD is characterized...

  • Depression
  • World
  • Depression Prevalence
  • Disability-Adjusted Life Years

Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes....

  • Therapy
  • Psychotic Disorder
  • Drug Development
  • Depression
  • Pharmaceutical
  • Mental Health
  • World
  • Health Provider Density

This study focuses on China’s Depression Treatment Drugs industry forecasts. In the two past decades, the industry has been growing at a fast pace. The dramatic expansions of the manufacturing capabilities and rising consumer consumptions in China have transformed China’s society and economy. China is one of the world’s...

  • Antidepressant
  • Depression
  • China
  • Industrial Production
  • Labour Force

This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Behavioral Rehabilitation Market By Application (Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Personality Disorder, Attention...

  • Mental Health
  • Specialty Hospital
  • Depression
  • Anxiety Disorder
  • World
  • Depression Prevalence

“Acetylcholine Receptor (AChR) Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Acetylcholine Receptor (AChR) Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment...

  • Therapy
  • Depression
  • World

Scope of the Report The report titled “Global Psychedelic Drugs Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)”, provides an in depth analysis of the global psychedelic drugs market by value, by indication, etc. The report also provides a detailed analysis of the COVID-19 impact on the psychedelic...

  • Mental Health
  • Therapy
  • Depression
  • Addiction Disorder
  • Clinical Trial
  • World
  • Depression Prevalence
  • Drug Approval

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018 Summary PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event....

  • Depression
  • Anxiety Disorder
  • Drug Approval
  • Prescription Drug Sales

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2018 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation...

  • Therapy
  • Psychotic Disorder
  • Drug Development
  • Depression
  • Mental Health
  • World
  • Health Provider Density
  • Prescription Drug Sales

Glutamate Receptor Ionotropic NMDA 2B (Glutamate [NMDA] Receptor Subunit Epsilon 2 or N Methyl D Aspartate Receptor Subtype 2B or N Methyl D Aspartate Receptor Subunit 3 or GRIN2B) - Pipeline Review, H2 2018 Summary According to the recently published report ’Glutamate Receptor Ionotropic NMDA 2B...

  • Therapy
  • Depression
  • Chronic Pain
  • World
  • Depression Prevalence
  • Prescription Drug Sales

ForeSights: Psychobiotics Summary Psychobiotics, a class of probiotic strains in the gut, are believed to help reduce stress and anxiety levels by producing the neuroactive compounds that control moods. This report is part of ForeSights series, which identifies weak signals and considers...

  • Depression
  • Healthcare
  • Beverage
  • Functional Food
  • World
  • Labour Utilisation
  • Health Insurance Claims

Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person’s ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of...

  • Depression
  • United States
  • Mental Health Expenditure
  • Spending On Medicines

Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H1 2018 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation...

  • Therapy
  • Psychotic Disorder
  • Drug Development
  • Depression
  • Mental Health
  • World
  • Health Provider Density
  • Prescription Drug Sales

Summary Nexstim Plc (Nexstim) focuses on navigated, non-invasive brain stimulation therapy and diagnosis based on E-field navigated neuro stimulation technology (eTMS).Its NBS system applies the technology for pre-surgical mapping of the motor and speech cortices. It is also used for research, therapy and neurosurgical...

  • Depression
  • Chronic Pain
  • Canada
  • Medical Devices Sales
  • Direct Sales

Drug Overview: Rexulti

8770 10000 7800

Drug Overview  Rexulti (brexpiprazole) is Otsuka’s latest atypical antipsychotic, approved simultaneously in the US for schizophrenia and major depressive disorder in July 2015. The drug acts similarly to Abilify (aripiprazole; Otsuka/Lundbeck), displaying partial agonism of dopamine receptors in the central nervous...

  • Antipsychotic
  • Neurology
  • Clinical Trial
  • Depression
  • United States

Drug Overview: Vraylar

8770 10000 7800

Drug Overview  Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor. Vraylar is also a partial agonist at 5-HT1A receptors and an antagonist at 5-HT2A receptors. Most atypical antipsychotics...

  • Antipsychotic
  • Depression

Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline...

  • Bipolar Disorder
  • Depression
  • World
  • Depression Prevalence
  • Diagnostic Imaging Density

Treatment Resistant Depression - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Treatment Resistant Depression - Pipeline Review, H2 2016, provides an overview of the Treatment Resistant Depression (Central Nervous System) pipeline landscape. Treatment...

  • Therapy
  • Depression
  • World
  • Drug Approval
  • Depression Prevalence

Major Depressive Disorder - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Major Depressive Disorder - Pipeline Review, H2 2016, provides an overview of the Major Depressive Disorder (Central Nervous System) pipeline landscape. Major depressive...

  • Depression
  • World
  • Depression Prevalence
  • Diagnostic Imaging Density

Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Glutamate Receptor Ionotropic NMDA 2B ( NMDA Receptor Subunit Epsilon 2 or GRIN2B) - Pipeline Review, H1 2016’, provides in depth analysis on Glutamate Receptor Ionotropic...

  • Depression
  • World
  • Depression Prevalence

Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person’s ability to...

  • Depression
  • World
  • United States
  • Drug Approval
  • Smoking Prevalence

Treatment Resistant Depression - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Treatment Resistant Depression - Pipeline Review, H1 2016’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development...

  • Therapy
  • Depression
  • Research And Development
  • World
  • Pharmaceutical Registrations
  • Drug Approval

Major Depressive Disorder - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘Major Depressive Disorder - Pipeline Review, H1 2016’, provides an overview of the Major Depressive Disorder pipeline landscape. The report provides comprehensive information on the therapeutics under development for Major...

  • Depression
  • World
  • European Union
  • Depression Prevalence
  • Diagnostic Imaging Density

About depression drugs According to the WHO, depression is a common mental disorder that contributes significantly to the global burden of disease. It affects people across communities worldwide. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness,...

  • Depression
  • Antidepressant
  • World
  • United States
  • Drug Approval
  • Depression Prevalence

FDA approval of Lundbeck and Otsuka Pharmaceuticals' Rexulti – which was announced last week – delivers a third atypical antipsychotic to the US market for the treatment of both schizophrenia and major depressive disorder (MDD). Rexulti will not only compete with...

  • Depression
  • Psychotic Disorder
  • Antipsychotic
  • United States
  • Drug Approval

About Depression According to the WHO, depression is a common mental disorder which contributes significantly to the global burden of disease. It affects people across communities in the world. It is characterized by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or appetite, feelings of tiredness,...

  • Depression
  • Antidepressant
  • United States
  • World
  • Depression Prevalence
  • Drug Approval